Sign in Subscribe
Cutaneous leishmaniasis

Delayed Hypersensitivity to Intralesional Meglumine Antimoniate for Cutaneous Leishmaniasis

Strategic Insights

— 1 min read

A recent study has highlighted the risk of an allergic response to meglumine antimoniate, a treatment for cutaneous leishmaniasis, which in rare cases can lead to severe and potentially life-threatening reactions. The study, conducted by researchers at University College London (UCL) Hospitals NHS Foundation Trust, describes a case of a 61-year-old male patient who developed an enlarging nodule on his earlobe after undergoing intralesional therapy with meglumine antimoniate. The patient experienced localized swelling, erythema, and an urticarial rash, prompting the discontinuation of treatment.

Key Takeaways:

  • The study warns clinicians treating leishmaniasis to be aware of the potential adverse effect of antimonials, which may require the use of alternative therapies.
  • The patient's case highlights the importance of monitoring patients for signs of allergic reactions during treatment with meglumine antimoniate.
  • The prevalence of pentavalent antimonial hypersensitivity varies between studies, with some reporting higher rates of adverse events.
  • The study recommends the use of alternative therapies for patients who experience allergic reactions to meglumine antimoniate.
  • The researchers stress the need for careful patient selection and monitoring to minimize the risk of adverse reactions.
  • The study cites a previous report of a patient who developed a similar reaction to another antimonial drug, meglumine antimoniate.
  • The researchers note that the reaction was characterized by mixed Type I and Type IV features, indicating a complex immune response.

Statistics:

  • The patient experienced localized swelling and erythema after each administration of meglumine antimoniate.
  • The patient's urticarial rash appeared on his hands after the second infiltration.
  • The reaction was classified as a mixed Type I and Type IV hypersensitivity reaction.
  • The patient was treated for 2 infiltrations before the reaction occurred.
  • The patient experienced full recovery 36 months after the first treatment.
  • The study notes that the prevalence of pentavalent antimonial hypersensitivity varies between studies, likely due to differences in reporting of adverse events.
  • The study reports that the patient declined further treatment and the lesion gradually resolved.

Sources:

  • NewsRx. Studies from University College London (UCL) Hospitals NHS Foundation Trust Have Provided New Data on Delayed Hypersensitivity (Delayed Hypersensitivity to Intralesional Meglumine Antimoniate for Cutaneous Leishmaniasis). World Disease Weekly. November 4, 2025; p 90.
  • The American Journal of Tropical Medicine and Hygiene. Delayed Hypersensitivity to Intralesional Meglumine Antimoniate for Cutaneous Leishmaniasis. 2025.
  • University College London (UCL) Hospitals NHS Foundation Trust. Delayed Hypersensitivity to Intralesional Meglumine Antimoniate for Cutaneous Leishmaniasis.

Read more